Director/PDMR Shareholding
October 23 2020 - 2:00AM
Director/PDMR Shareholding
DXS INTERNATIONAL PLC
Notification of Director / PDMR Dealing
The Board of DXS International plc (the
“Company”), the AQSE Growth Market quoted clinical decision support
developer and supplier of clinical decision support systems has
received notification that on 22 October 2020 Mr Bob Sutcliffe, the
Chairman, purchased 14,814 Ordinary Shares in the Company at a
price of 6.75p per share.
Following the transaction specified above Mr
Sutcliffe has a beneficial holding of 532,049 Ordinary Shares
representing 1.10% of the issued share capital of the Company.
|
1 |
Details of the person discharging managerial
responsibilities / person closely associated |
|
a) |
Name |
Robert Sutcliffe |
|
2 |
Reason for the notification |
|
a) |
Position/status |
Chairman |
|
b) |
Initial notification /Amendment |
Initial |
|
3 |
Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor |
|
a) |
Name |
DXS INTERNATIONAL PLC |
|
b) |
LEI |
2138001R1KEUWTXEVJ44 |
|
4 |
Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted |
|
a) |
Description of the financial instrument, type of instrument |
Ordinary Shares of 0.33p each |
|
|
|
|
Identification code |
ISIN GB00B2Q6HZ92 |
|
|
|
|
b) |
Nature of the transaction |
Purchase |
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
6.75p |
14,814 |
|
|
|
|
|
|
|
|
d) |
Aggregated information |
|
|
|
|
|
- Aggregated volume |
|
|
|
|
|
- Price |
|
|
|
|
|
e) |
Date of the transaction |
22 October 2020 |
|
f) |
Place of the transaction |
AQSE |
The Directors of DXS International plc accept
responsibility for this announcement
Enquiries:
| David
Immelman (Chief
Executive)DXS International plc |
01252 719800david@dxs-systems.com |
| Wrecclesham
HouseWrecclesham RoadFarnhamSurreyGU10 4PS |
|
|
www.dxs-systems.co.uk |
|
| Corporate
Advisor |
|
| David
PapworthCity & Merchant |
0207 101 7676 |
| Corporate
Broker |
|
| Hybridan
LLPClaire Louise Noyce |
020 3764 2341 |
Note to Editors:
DXS International presents up to date treatment
guidelines and recommendations, from Clinical Commissioning Groups
and other trusted NHS sources, to doctors, nurses and pharmacists
in their workflow and during the patient consultation. This
effective clinical decision support ultimately translates to
improved healthcare outcomes delivered more cost effectively which
should significantly contribute towards the NHS achieving its
projected efficiency savings.
DXS (AQSE:DXSP)
Historical Stock Chart
From Jun 2024 to Jul 2024
DXS (AQSE:DXSP)
Historical Stock Chart
From Jul 2023 to Jul 2024
